Clinical trial
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV…
NCT00003002 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00003002 |
|---|---|
| Title | HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer |
| Official title | A Phase I Study of a HER-2/Neu Peptide Based Vaccine With GM-CSF as an Adjuvant in Patients With Advanced Stage HER-2/Neu Expressing Cancers |
| Lead sponsor | University of Washington, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Lung Cancer, Ovarian Cancer |
| Intervention type | Biological |
| Interventions | HER-2/neu peptide vaccine, sargramostim |
| Enrollment | 60 |
| Start date | Apr 1, 1996 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Jul 30, 2004 |
| Last update posted | Feb 27, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: